经脐单孔腹腔镜胆囊切除术对胆囊结石患者胃肠功能和血清固醇激素调节元件结合蛋白2水平的影响

Effects of transumbilical single-hole laparoscopic cholecystectomy on gastrointestinal function and serum SREBP-2 level in patients with cholecystolithiasis

摘要:

目的 探讨经脐单孔腹腔镜胆囊切除术（TUSPLC）对胆囊结石患者胃肠功能和血清固醇激素调节元件结合蛋白2（SREBP-2）水平的影响。方法 选取2021年9月－2022年8月于该院治疗的100例胆囊结石患者作为研究对象，采取随机数表法分为对照组和研究组，各50例。对照组行腹腔镜胆囊切除术（LC），研究组行TUSPLC，比较两组患者临床疗效。结果 两组患者术中出血量比较，差异无统计学意义（P > 0.05）；研究组手术时间长于对照组，住院时间、肛门排气时间、进食时间、肠鸣音恢复时间和排便时间短于对照组，差异均有统计学意义（P < 0.05）。术前，两组患者麦吉尔布里斯班症状评分（MBSS）、血清SREBP-2、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）比较，差异均无统计学意义（P > 0.05）；术后3个月，两组患者MBSS、血清SREBP-2、IL-6和TNF-α较术前降低，且研究组降低幅度大于对照组，差异均有统计学意义（P < 0.05）；两组患者并发症发生率比较，差异无统计学意义（P > 0.05）。结论 TUSPLC治疗胆囊结石的效果确切，可降低血清SREBP-2和炎症因子水平，促进患者胃肠功能恢复，安全性高。

Abstract:

Objective To investigate the impacts of transumbilical single-port laparoscopic cholecystectomy (TUSPLC) on gastrointestinal function and serum sterol regulatory element-binding protein-2 (SREBP-2) level in patients with cholecystolithiasis.Methods 100 patients with cholecystolithiasis from September 2021 to August 2022 were selected as the study objects, and divided them into control group and study group by random number table method, with 50 cases in each group. The control group underwent laparoscopic cholecystectomy, study group underwent TUSPLC, the efficacy of the two groups was compared.Results The intraoperative blood loss of patients treated with different treatment methods showed no difference (P > 0.05). Patients treated with TUSPLC had longer operation time, and shorter hospital stay, the anal exhaust time, feeding time, bowel sound recovery time and defecation time compared with control group (P < 0.05). Before operation, there were no differences in McGill Brisbane symptom score (MBSS), serum SREBP-2, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) between the two groups (P > 0.05). Three months after surgery, the MBSS, serum SREBP-2, IL-6 and TNF-α were decreased compared with before the surgery in two groups, and the change in the study group was greater compared with control group, the differences were statistically significant (P < 0.05). There was no difference in the incidence of complications (P > 0.05).Conclusion TUSPLC has a definite effect in the treatment of cholecystolithiasis, can reduce the levels of serum SREBP-2 and inflammatory factors in patients, and can improve the gastrointestinal function of patients with high safety.